{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:44:39Z","timestamp":1794008679947,"version":"4.8.0"},"reference-count":182,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-026-01703-w","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:02:38Z","timestamp":1782723758000},"page":"1811-1827","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The evolving role of cytokines for CAR-T cell manufacturing and beyond"],"prefix":"10.1038","volume":"10","author":[{"given":"Mar","family":"Guaza-Lasheras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Nimmerfroh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0322-5059","authenticated-orcid":false,"given":"Dominic","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja D.","family":"de Gruijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9372-8954","authenticated-orcid":false,"given":"Jessica","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7594-7280","authenticated-orcid":false,"given":"Christian","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8910-5620","authenticated-orcid":false,"given":"Heinz","family":"L\u00e4ubli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Lotem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Mittelstaet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Paget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5937-4344","authenticated-orcid":false,"given":"Sine Reker","family":"Hadrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5040-6426","authenticated-orcid":false,"given":"Sonja","family":"Schallenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Thor Straten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Theurich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Venetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Zippelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Zitvogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5612-4673","authenticated-orcid":false,"given":"Sebastian","family":"Kobold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"1703_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1182\/blood.2023023419","volume":"144","author":"J Kim","year":"2024","unstructured":"Kim, J. et al. CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis. Blood 144, 629\u2013638 (2024).","journal-title":"Blood"},{"key":"1703_CR2","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).","journal-title":"Sci. Transl. Med."},{"key":"1703_CR3","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725\u2013733 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1703_CR4","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509\u20131518 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1703_CR5","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189\u20131198 (2022).","journal-title":"Nat. Med."},{"key":"1703_CR6","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen, A. et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat. Med. 29, 2844\u20132853 (2023).","journal-title":"Nat. Med."},{"key":"1703_CR7","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje, M. et al. Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature 637, 708\u2013715 (2025).","journal-title":"Nature"},{"key":"1703_CR8","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","volume":"30","author":"TB Dorff","year":"2024","unstructured":"Dorff, T. B. et al. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med. 30, 1636\u20131644 (2024).","journal-title":"Nat. Med."},{"key":"1703_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/CJI.0b013e318194a6e8","volume":"32","author":"D Hollyman","year":"2009","unstructured":"Hollyman, D. et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J. Immunother. 32, 169\u2013180 (2009).","journal-title":"J. Immunother."},{"key":"1703_CR10","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2024","unstructured":"Steffin, D. et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature 637, 940\u2013946 (2024).","journal-title":"Nature"},{"key":"1703_CR11","first-page":"2023","volume":"2022","author":"AR Saez-Iba\u00f1ez","year":"2024","unstructured":"Saez-Iba\u00f1ez, A. R. et al. The changing landscape of cancer cell therapies: clinical trials and real-world data. Nat. Rev. Drug Discov. 2022, 2023\u20132024 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1703_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","volume":"60","author":"A Rampotas","year":"2025","unstructured":"Rampotas, A., Richter, J., Isenberg, D. & Roddie, C. CAR-T cell therapy embarks on autoimmune disease. Bone Marrow Transplant 60, 6\u20139 (2025).","journal-title":"Bone Marrow Transplant"},{"key":"1703_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller, F. et al. CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1703_CR14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1126\/science.181845","volume":"193","author":"DA Morgan","year":"1976","unstructured":"Morgan, D. A., Ruscetti, F. W. & Gallo, R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193, 1007\u20131008 (1976).","journal-title":"Science"},{"key":"1703_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/268154a0","volume":"268","author":"S Gillis","year":"1977","unstructured":"Gillis, S. & Smith, K. A. Long term culture of tumour-specific cytotoxic T cells. Nature 268, 154\u2013156 (1977).","journal-title":"Nature"},{"key":"1703_CR16","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nri2580","volume":"9","author":"Y Rochman","year":"2009","unstructured":"Rochman, Y., Spolski, R. & Leonard, W. J. New insights into the regulation of T cells by \u03b3c family cytokines. Nat. Rev. Immunol. 9, 480\u2013490 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"1703_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","volume":"128","author":"M Sabatino","year":"2016","unstructured":"Sabatino, M. et al. Generation of clinical-grade CD19-specific CAR-modified CD81 memory stem cells for the treatment of human B-cell malignancies. Blood 128, 519\u2013528 (2016).","journal-title":"Blood"},{"key":"1703_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aal1253","volume":"11","author":"P Gonnord","year":"2018","unstructured":"Gonnord, P. et al. A hierarchy of affinities between cytokine receptors and the common gamma chain leads to pathway cross-talk. Sci. Signal. 11, eaal1253 (2018).","journal-title":"Sci. Signal."},{"key":"1703_CR19","doi-asserted-by":"crossref","unstructured":"Moraga, I., Spangler, J., Mendoza, J. L. & Garcia, K. C. in Advances in Immunology Vol. 121 (ed. Alt, F. W.) Ch. 1 (Elsevier, 2014).","DOI":"10.1016\/B978-0-12-800100-4.00001-5"},{"key":"1703_CR20","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290\u20131297 (2011).","journal-title":"Nat. Med."},{"key":"1703_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109411","volume":"27","author":"S Wang","year":"2024","unstructured":"Wang, S. et al. Exogenous IL-2 delays memory precursors generation and is essential for enhancing memory cells effector functions. iScience 27, 109411 (2024).","journal-title":"iScience"},{"key":"1703_CR22","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu, Y. et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123, 3750\u20133759 (2014).","journal-title":"Blood"},{"key":"1703_CR23","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1182\/blood-2024-210324","volume":"144","author":"CR Hopkins","year":"2024","unstructured":"Hopkins, C. R. et al. In vivo persistence and function of CAR19 T-cell products for pediatric B-cell acute lymphoblastic leukemia are impacted by media, cytokine supplementation and metabolite bioavailability during ex vivo manufacturing. Blood 144, 3473\u20133474 (2024).","journal-title":"Blood"},{"key":"1703_CR24","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jcyt.2017.03.067","volume":"19","author":"T Kaartinen","year":"2017","unstructured":"Kaartinen, T. et al. Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion. Cytotherapy 19, 689\u2013702 (2017).","journal-title":"Cytotherapy"},{"key":"1703_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1284722","volume":"6","author":"X Wei","year":"2017","unstructured":"Wei, X. et al. PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. Oncoimmunology 6, e1284722 (2017).","journal-title":"Oncoimmunology"},{"key":"1703_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10940-8","volume":"7","author":"OO Yeku","year":"2017","unstructured":"Yeku, O. O., Purdon, T. J., Koneru, M., Spriggs, D. & Brentjens, R. J. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci. Rep. 7, 10541 (2017).","journal-title":"Sci. Rep."},{"key":"1703_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.04.008","volume":"484","author":"\u00c1 Sz\u00f6\u0151r","year":"2020","unstructured":"Sz\u00f6\u0151r, \u00c1 et al. Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies. Cancer Lett. 484, 1\u20138 (2020).","journal-title":"Cancer Lett."},{"key":"1703_CR28","doi-asserted-by":"publisher","first-page":"11054","DOI":"10.18632\/aging.102510","volume":"11","author":"Y Liu","year":"2019","unstructured":"Liu, Y. et al. EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC. Aging 11, 11054\u201311072 (2019).","journal-title":"Aging"},{"key":"1703_CR29","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1089\/hum.2018.229","volume":"30","author":"BL Zhang","year":"2019","unstructured":"Zhang, B. L. et al. Preclinical evaluation of chimeric antigen receptor-modified T cells specific to epithelial cell adhesion molecule for treating colorectal cancer. Hum. Gene Ther. 30, 402\u2013412 (2019).","journal-title":"Hum. Gene Ther."},{"key":"1703_CR30","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1007\/s00432-021-03613-7","volume":"147","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients. J. Cancer Res. Clin. Oncol. 147, 3725\u20133734 (2021).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1703_CR31","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","volume":"9","author":"K Feng","year":"2018","unstructured":"Feng, K. et al. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein Cell 9, 838\u2013847 (2018).","journal-title":"Protein Cell"},{"key":"1703_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/jitc-2025-011698","volume":"13","author":"D Andreu-Sanz","year":"2025","unstructured":"Andreu-Sanz, D. et al. Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis. J. Immunother. Cancer 13, 3\u20135 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"1703_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03315-3","volume":"24","author":"T Chen","year":"2024","unstructured":"Chen, T., Wang, M., Chen, Y. & Liu, Y. Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer Cell Int. 24, 133 (2024).","journal-title":"Cancer Cell Int."},{"key":"1703_CR34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.omto.2019.08.002","volume":"15","author":"Z Ying","year":"2019","unstructured":"Ying, Z. et al. Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin\u2019s lymphoma. Mol. Ther. Oncolytics 15, 60\u201368 (2019).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1703_CR35","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","volume":"184","author":"CR Good","year":"2021","unstructured":"Good, C. R. et al. An NK-like CAR T cell transition in CAR T cell dysfunction. Cell 184, 6081\u20136100.e26 (2021).","journal-title":"Cell"},{"key":"1703_CR36","doi-asserted-by":"crossref","unstructured":"Wang, D. et al. In vitro tumor cell rechallenge for predictive evaluation of chimeric antigen receptor T cell antitumor function. J. Vis. Exp. 10.3791\/59275 (2019).","DOI":"10.3791\/59275-v"},{"key":"1703_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1626369","volume":"16","author":"M Jassin","year":"2025","unstructured":"Jassin, M. et al. From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumors. Front. Immunol. 16, 1626369 (2025).","journal-title":"Front. Immunol."},{"key":"1703_CR38","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.3390\/cancers16183186","volume":"16","author":"EN Ahmed","year":"2024","unstructured":"Ahmed, E. N., Cutmore, L. C. & Marshall, J. F. Syngeneic mouse models for pre-clinical evaluation of CAR T cells. Cancers 16, 3186 (2024).","journal-title":"Cancers"},{"key":"1703_CR39","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.omtm.2021.09.014","volume":"23","author":"A Michels","year":"2021","unstructured":"Michels, A. et al. Lentiviral and adeno-associated vectors efficiently transduce mouse T lymphocytes when targeted to murine CD8. Mol. Ther. Methods Clin. Dev. 23, 334\u2013347 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1703_CR40","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.49392","volume":"9","author":"D Kato","year":"2020","unstructured":"Kato, D. et al. GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab. eLife 9, e49392 (2020).","journal-title":"eLife"},{"key":"1703_CR41","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/(SICI)1521-2254(199909\/10)1:5<341::AID-JGM58>3.0.CO;2-J","volume":"1","author":"AB Hagani","year":"1999","unstructured":"Hagani, A. B., Rivi\u00e8re, I., Tan, C., Krause, A. & Sadelain, M. Activation conditions determine susceptibility of murine primary T-lymphocytes to retroviral infection. J. Gene Med. 1, 341\u2013351 (1999).","journal-title":"J. Gene Med."},{"key":"1703_CR42","doi-asserted-by":"publisher","first-page":"e20192203","DOI":"10.1084\/jem.20192203","volume":"218","author":"E Lanitis","year":"2021","unstructured":"Lanitis, E. et al. Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. J. Exp. Med. 218, e20192203 (2021).","journal-title":"J. Exp. Med."},{"key":"1703_CR43","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201708662","volume":"12","author":"R Stripecke","year":"2020","unstructured":"Stripecke, R. et al. Innovations, challenges and minimal information for standardization of humanized mice. EMBO Mol. Med. 12, e8662 (2020).","journal-title":"EMBO Mol. Med."},{"key":"1703_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37785-2","volume":"14","author":"X Hu","year":"2023","unstructured":"Hu, X. et al. Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice. Nat. Commun. 14, 2020 (2023).","journal-title":"Nat. Commun."},{"key":"1703_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19420862.2017.1389364","volume":"10","author":"FR Brennan","year":"2018","unstructured":"Brennan, F. R. et al. Safety testing of monoclonal antibodies in non-human primates: case studies highlighting their impact on human risk assessment. MAbs 10, 1\u201317 (2018).","journal-title":"MAbs"},{"key":"1703_CR46","doi-asserted-by":"publisher","first-page":"e1207","DOI":"10.1002\/cti2.1207","volume":"9","author":"H Morokawa","year":"2020","unstructured":"Morokawa, H. et al. Autologous non-human primate model for safety assessment of piggyBac transposon-mediated chimeric antigen receptor T cells on granulocyte-macrophage colony-stimulating factor receptor. Clin. Transl. Immunol. 9, e1207 (2020).","journal-title":"Clin. Transl. Immunol."},{"key":"1703_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1291","volume":"10","author":"S Yagyu","year":"2021","unstructured":"Yagyu, S. et al. A lymphodepleted non-human primate model for the assessment of acute on-target and off-tumor toxicity of human chimeric antigen receptor-T cells. Clin. Transl. Immunol. 10, e1291 (2021).","journal-title":"Clin. Transl. Immunol."},{"key":"1703_CR48","doi-asserted-by":"publisher","first-page":"101784","DOI":"10.1016\/j.xpro.2022.101784","volume":"3","author":"GI Ellis","year":"2022","unstructured":"Ellis, G. I. et al. Generation of non-human primate CAR Tregs using artificial antigen-presenting cells, simian tropic lentiviral vectors, and antigen-specific restimulation. STAR Protoc. 3, 101784 (2022).","journal-title":"STAR Protoc."},{"key":"1703_CR49","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/toxsci\/kfaa098","volume":"177","author":"C Karbowski","year":"2020","unstructured":"Karbowski, C. et al. Nonclinical safety assessment of AMG 553, an investigational chimeric antigen receptor T-cell therapy for the treatment of acute myeloid leukemia. Toxicol. Sci. 177, 94\u2013107 (2020).","journal-title":"Toxicol. Sci."},{"key":"1703_CR50","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang, X. & Rivi\u00e8re, I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol. Ther. Oncolytics 3, 16015 (2016).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1703_CR51","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/cells13020146","volume":"13","author":"C Lonez","year":"2024","unstructured":"Lonez, C. & Breman, E. Allogeneic CAR-T therapy technologies: has the promise been met? Cells 13, 146 (2024).","journal-title":"Cells"},{"key":"1703_CR52","doi-asserted-by":"publisher","first-page":"114361","DOI":"10.1016\/j.ejpb.2024.114361","volume":"201","author":"KD S S","year":"2024","unstructured":"S S, K. D. et al. Regulatory landscape and challenges in CAR-T cell therapy development in the US, EU, Japan and India. Eur. J. Pharm. Biopharm. 201, 114361 (2024).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"1703_CR53","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-1759(90)90210-M","volume":"128","author":"SR Riddell","year":"1990","unstructured":"Riddell, S. R. & Greenberg, P. D. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J. Immunol. Methods 128, 189\u2013201 (1990).","journal-title":"J. Immunol. Methods"},{"key":"1703_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1453740","volume":"15","author":"M Benavidez Arias","year":"2024","unstructured":"Benavidez Arias, M., Nguyen, A., Ross, D., Eagerton, D. & Ritthipichai, K. Lighting the way: an economical alternative to feeder cell irradiation for T-cell expansion. Front. Immunol. 15, 1453740 (2024).","journal-title":"Front. Immunol."},{"key":"1703_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1032397","volume":"13","author":"H Singh","year":"2022","unstructured":"Singh, H. et al. Sleeping beauty generated CD19 CAR T-cell therapy for advanced B-cell hematological malignancies. Front. Immunol. 13, 1032397 (2022).","journal-title":"Front. Immunol."},{"key":"1703_CR56","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1039\/D3LC00622K","volume":"24","author":"H Kim","year":"2024","unstructured":"Kim, H., Kim, S., Lim, H. & Chung, A. J. Expanding CAR-T cell immunotherapy horizons through microfluidics. Lab Chip 24, 1088\u20131120 (2024).","journal-title":"Lab Chip"},{"key":"1703_CR57","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.neuropharm.2016.02.013","volume":"120","author":"SR Choudhury","year":"2017","unstructured":"Choudhury, S. R. et al. Viral vectors for therapy of neurologic diseases. Neuropharmacology 120, 63\u201380 (2017).","journal-title":"Neuropharmacology"},{"key":"1703_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06524-0","volume":"23","author":"L Dan","year":"2025","unstructured":"Dan, L. & Kang-Zheng, L. Optimizing viral transduction in immune cell therapy manufacturing: key process design considerations. J. Transl. Med. 23, 501 (2025).","journal-title":"J. Transl. Med."},{"key":"1703_CR59","doi-asserted-by":"publisher","first-page":"122683","DOI":"10.1016\/j.lfs.2024.122683","volume":"348","author":"Y Metanat","year":"2024","unstructured":"Metanat, Y. et al. The paths toward non-viral CAR-T cell manufacturing: a comprehensive review of state-of-the-art methods. Life Sci. 348, 122683 (2024).","journal-title":"Life Sci."},{"key":"1703_CR60","doi-asserted-by":"publisher","first-page":"e68201","DOI":"10.1371\/journal.pone.0068201","volume":"8","author":"AC Field","year":"2013","unstructured":"Field, A. C. et al. Comparison of lentiviral and Sleeping Beauty mediated \u03b1\u03b2 T cell receptor gene transfer. PLoS ONE 8, e68201 (2013).","journal-title":"PLoS ONE"},{"key":"1703_CR61","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/j.ymthe.2021.08.013","volume":"29","author":"A Schambach","year":"2021","unstructured":"Schambach, A., Morgan, M. & Fehse, B. Two cases of T cell lymphoma following Piggybac-mediated CAR T cell therapy. Mol. Ther. 29, 2631\u20132633 (2021).","journal-title":"Mol. Ther."},{"key":"1703_CR62","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1089\/crispr.2019.0006","volume":"2","author":"E Rayner","year":"2019","unstructured":"Rayner, E. et al. CRISPR\u2013Cas9 causes chromosomal instability and rearrangements in cancer cell lines, detectable by cytogenetic methods. Cris. J. 2, 406\u2013416 (2019).","journal-title":"Cris. J."},{"key":"1703_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12740-6","volume":"7","author":"K Boroviak","year":"2017","unstructured":"Boroviak, K., Fu, B., Yang, F., Doe, B. & Bradley, A. Revealing hidden complexities of genomic rearrangements generated with Cas9. Sci. Rep. 7, 12867 (2017).","journal-title":"Sci. Rep."},{"key":"1703_CR64","doi-asserted-by":"publisher","first-page":"5855","DOI":"10.1038\/s41467-021-26097-y","volume":"12","author":"S Papathanasiou","year":"2021","unstructured":"Papathanasiou, S. et al. Whole chromosome loss and genomic instability in mouse embryos after CRISPR\u2013Cas9 genome editing. Nat. Commun. 12, 5855 (2021).","journal-title":"Nat. Commun."},{"key":"1703_CR65","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2623","volume":"31","author":"Y Fu","year":"2013","unstructured":"Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR\u2013Cas nucleases in human cells. Nat. Biotechnol. 31, 822\u2013826 (2013).","journal-title":"Nat. Biotechnol."},{"key":"1703_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30480-8","volume":"13","author":"M Kosicki","year":"2022","unstructured":"Kosicki, M. et al. Cas9-induced large deletions and small indels are controlled in a convergent fashion. Nat. Commun. 13, 3422 (2022).","journal-title":"Nat. Commun."},{"key":"1703_CR67","doi-asserted-by":"publisher","first-page":"101250","DOI":"10.1016\/j.omtm.2024.101250","volume":"32","author":"J Dias","year":"2024","unstructured":"Dias, J., Garcia, J., Agliardi, G. & Roddie, C. CAR-T cell manufacturing landscape\u2014lessons from the past decade and considerations for early clinical development. Mol. Ther. Methods Clin. Dev. 32, 101250 (2024).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1703_CR68","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1182\/blood.2021010858","volume":"138","author":"KP Micklethwaite","year":"2021","unstructured":"Micklethwaite, K. P. et al. Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood 138, 1391\u20131405 (2021).","journal-title":"Blood"},{"key":"1703_CR69","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","volume":"25","author":"A Bot","year":"2026","unstructured":"Bot, A. et al. In vivo chimeric antigen receptor (CAR)-T cell therapy. Nat. Rev. Drug Discov. 25, 116\u2013137 (2026).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1703_CR70","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","volume":"7","author":"D Alizadeh","year":"2019","unstructured":"Alizadeh, D. et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol. Res. 7, 759\u2013772 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"1703_CR71","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.ymthe.2025.02.031","volume":"33","author":"X Wang","year":"2025","unstructured":"Wang, X., Liao, Y., Liu, D., Zheng, J. & Shi, M. Presetting CAR-T cells during ex vivo biomanufacturing. Mol. Ther. 33, 1380\u20131406 (2025).","journal-title":"Mol. Ther."},{"key":"1703_CR72","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s13238-019-0643-y","volume":"10","author":"J Zhou","year":"2019","unstructured":"Zhou, J. et al. Chimeric antigen receptor T (CAR-T) cells expanded with IL-7\/IL-15 mediate superior antitumor effects. Protein Cell 10, 764\u2013769 (2019).","journal-title":"Protein Cell"},{"key":"1703_CR73","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1002\/ijc.33156","volume":"147","author":"T Ran","year":"2020","unstructured":"Ran, T., Eichm\u00fcller, S. B., Schmidt, P. & Schlander, M. Cost of decentralized CAR T-cell production in an academic nonprofit setting. Int. J. Cancer 147, 3438\u20133445 (2020).","journal-title":"Int. J. Cancer"},{"key":"1703_CR74","doi-asserted-by":"publisher","first-page":"107868","DOI":"10.1016\/j.bej.2020.107868","volume":"167","author":"RM Comisel","year":"2021","unstructured":"Comisel, R. M., Kara, B., Fiesser, F. H. & Farid, S. S. Lentiviral vector bioprocess economics for cell and gene therapy commercialization. Biochem. Eng. J. 167, 107868 (2021).","journal-title":"Biochem. Eng. J."},{"key":"1703_CR75","unstructured":"Mast, J. A faster, simpler, cheaper cancer cell therapy is about to be tested in humans. STAT https:\/\/www.statnews.com\/2024\/07\/09\/interius-in-vivo-car-t-cancer\/ (2024)."},{"key":"1703_CR76","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2023","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 (2023).","journal-title":"Science"},{"key":"1703_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.675179","volume":"8","author":"L Du","year":"2021","unstructured":"Du, L. et al. IL-21 optimizes the CAR-T cell preparation through improving lentivirus mediated transfection efficiency of T cells and enhancing CAR-T cell cytotoxic activities. Front. Mol. Biosci. 8, 675179 (2021).","journal-title":"Front. Mol. Biosci."},{"key":"1703_CR78","doi-asserted-by":"publisher","first-page":"eabg6986","DOI":"10.1126\/scitranslmed.abg6986","volume":"13","author":"Q Zhang","year":"2021","unstructured":"Zhang, Q. et al. A human orthogonal IL-2 and IL-2R\u03b2 system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia. Sci. Transl. Med. 13, eabg6986 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1703_CR79","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.immuni.2025.10.024","volume":"59","author":"H Jiang","year":"2026","unstructured":"Jiang, H. et al. IL-9 as a naturally orthogonal cytokine with optimal JAK\/STAT signaling for engineered T cell therapy. Immunity 59, 177\u2013194.e12 (2026).","journal-title":"Immunity"},{"key":"1703_CR80","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ymthe.2020.09.027","volume":"29","author":"V Ort\u00edz-Maldonado","year":"2021","unstructured":"Ort\u00edz-Maldonado, V. et al. CART19-BE-01: a multicenter trial of ARI-0001 cell therapy in patients with CD19+ relapsed\/refractory malignancies. Mol. Ther. 29, 636\u2013644 (2021).","journal-title":"Mol. Ther."},{"key":"1703_CR81","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41409-021-01463-y","volume":"57","author":"E Trias","year":"2022","unstructured":"Trias, E., Juan, M., Urbano-Ispizua, A. & Calvo, G. The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001. Bone Marrow Transplant 57, 156\u2013159 (2022).","journal-title":"Bone Marrow Transplant"},{"key":"1703_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.156049","volume":"160","author":"H Winer","year":"2022","unstructured":"Winer, H. et al. IL-7: comprehensive review. Cytokine 160, 156049 (2022).","journal-title":"Cytokine"},{"key":"1703_CR83","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1182\/bloodadvances.2023010607","volume":"8","author":"SY Wang","year":"2024","unstructured":"Wang, S. Y. et al. Nonactivated and IL-7 cultured CD19-specific CAR T cells are enriched in stem cell phenotypes and functionally superior. Blood Adv. 8, 324\u2013335 (2024).","journal-title":"Blood Adv."},{"key":"1703_CR84","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.4049\/jimmunol.180.8.5309","volume":"180","author":"A Chandele","year":"2008","unstructured":"Chandele, A. et al. Formation of IL-7R\u03b1 high and IL-7R\u03b1 low CD8 T cells during infection is regulated by the opposing functions of GABP\u03b1 and Gfi-1. J. Immunol. 180, 5309\u20135319 (2008).","journal-title":"J. Immunol."},{"key":"1703_CR85","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nri2023","volume":"7","author":"R Mazzucchelli","year":"2007","unstructured":"Mazzucchelli, R. & Durum, S. K. Interleukin-7 receptor expression: intelligent design. Nat. Rev. Immunol. 7, 144\u2013154 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"1703_CR86","first-page":"3877","volume":"8","author":"J Lu","year":"2002","unstructured":"Lu, J. et al. Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin. Cancer Res. 8, 3877\u20133884 (2002).","journal-title":"Clin. Cancer Res."},{"key":"1703_CR87","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/1078-0432.CCR-12-2143","volume":"19","author":"SK Perna","year":"2013","unstructured":"Perna, S. K. et al. Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin. Cancer Res. 19, 106\u2013117 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1703_CR88","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.3390\/cancers13143534","volume":"13","author":"AM Battram","year":"2021","unstructured":"Battram, A. M. et al. Il-15 enhances the persistence and function of BCMA-targeting CAR-T cells compared to IL-2 or IL-15\/IL-7 by limiting CAR-T cell dysfunction and differentiation. Cancers 13, 3534 (2021).","journal-title":"Cancers"},{"key":"1703_CR89","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1182\/blood-2009-09-241398","volume":"115","author":"JC Markley","year":"2010","unstructured":"Markley, J. C. & Sadelain, M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 115, 3508\u20133519 (2010).","journal-title":"Blood"},{"key":"1703_CR90","doi-asserted-by":"publisher","first-page":"5326","DOI":"10.1182\/blood-2007-09-113050","volume":"111","author":"CS Hinrichs","year":"2008","unstructured":"Hinrichs, C. S. et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111, 5326\u20135333 (2008).","journal-title":"Blood"},{"key":"1703_CR91","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1158\/1078-0432.CCR-23-1872","volume":"30","author":"R Nguyen","year":"2024","unstructured":"Nguyen, R. et al. Cooperative armoring of CAR and TCR T-cells by T cell- restricted IL-15 and IL-21 universally enhances solid tumor efficacy. Clin. Cancer Res. 30, 1555\u20131566 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1703_CR92","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/CJI.0000000000000229","volume":"41","author":"Y Chen","year":"2018","unstructured":"Chen, Y. et al. Adoptive transfer of interleukin-21-stimulated human CD8+ T memory stem cells efficiently inhibits tumor growth. J. Immunother. 41, 274\u2013283 (2018).","journal-title":"J. Immunother."},{"key":"1703_CR93","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1074-7613(02)00367-9","volume":"17","author":"TR Malek","year":"2002","unstructured":"Malek, T. R., Yu, A., Vincek, V., Scibelli, P. & Kong, L. CD4 regulatory T cells prevent lethal autoimmunity in IL-2R\u03b2-deficient mice: implications for the nonredundant function of IL-2. Immunity 17, 167\u2013178 (2002).","journal-title":"Immunity"},{"key":"1703_CR94","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/ni.3540","volume":"17","author":"T Chinen","year":"2016","unstructured":"Chinen, T. et al. An essential role for the IL-2 receptor in Treg cell function. Nat. Immunol. 17, 1322\u20131333 (2016).","journal-title":"Nat. Immunol."},{"key":"1703_CR95","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.immuni.2005.01.016","volume":"22","author":"JD Fontenot","year":"2005","unstructured":"Fontenot, J. D. et al. Regulatory T cell lineage specification by the forkhead transcription factor Foxp3. Immunity 22, 329\u2013341 (2005).","journal-title":"Immunity"},{"key":"1703_CR96","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","volume":"155","author":"S Sakaguchi","year":"1995","unstructured":"Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151\u20131164 (1995).","journal-title":"J. Immunol."},{"key":"1703_CR97","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","volume":"610","author":"L Codarri Deak","year":"2022","unstructured":"Codarri Deak, L. et al. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells. Nature 610, 161\u2013172 (2022).","journal-title":"Nature"},{"key":"1703_CR98","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1158\/2159-8290.CD-23-1266","volume":"14","author":"KD Moynihan","year":"2024","unstructured":"Moynihan, K. D. et al. IL2 targeted to CD8+ T cells promotes robust effector T-cell responses and potent antitumor immunity. Cancer Discov. 14, 1206\u20131225 (2024).","journal-title":"Cancer Discov."},{"key":"1703_CR99","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1182\/blood-2024-198249","volume":"144","author":"S Sleiman","year":"2024","unstructured":"Sleiman, S. et al. Selective support of CAR-T cell therapies by cis-targeted IL-2 enhances anti-tumor activity and obviates the need for lymphodepletion in non-human primates. Blood 144, 499\u2013500 (2024).","journal-title":"Blood"},{"key":"1703_CR100","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1038\/s41590-024-01993-9","volume":"25","author":"Y Shi","year":"2024","unstructured":"Shi, Y. & Sadelain, M. Targeting systemic IL-2 to BCMA CAR-T cells. Nat. Immunol. 25, 1988\u20131990 (2024).","journal-title":"Nat. Immunol."},{"key":"1703_CR101","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s12551-013-0133-z","volume":"6","author":"JL Silva-Filho","year":"2014","unstructured":"Silva-Filho, J. L., Caruso-Neves, C. & Pinheiro, A. A. S. IL-4: an important cytokine in determining the fate of T cells. Biophys. Rev. 6, 111\u2013118 (2014).","journal-title":"Biophys. Rev."},{"key":"1703_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.684642","volume":"12","author":"M Bell","year":"2021","unstructured":"Bell, M. & Gottschalk, S. Engineered cytokine signaling to improve CAR T cell effector function. Front. Immunol. 12, 684642 (2021).","journal-title":"Front. Immunol."},{"key":"1703_CR103","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41586-024-07962-4","volume":"634","author":"B Feng","year":"2024","unstructured":"Feng, B. et al. The type 2 cytokine Fc\u2013IL-4 revitalizes exhausted CD8+ T cells against cancer. Nature 634, 712\u2013720 (2024).","journal-title":"Nature"},{"key":"1703_CR104","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41586-024-07762-w","volume":"634","author":"Z Bai","year":"2024","unstructured":"Bai, Z. et al. Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission. Nature 634, 702\u2013711 (2024).","journal-title":"Nature"},{"key":"1703_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51978-3","volume":"15","author":"CM Stewart","year":"2024","unstructured":"Stewart, C. M. et al. IL-4 drives exhaustion of CD8+ CART cells. Nat. Commun. 15, 7921 (2024).","journal-title":"Nat. Commun."},{"key":"1703_CR106","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nri2848","volume":"10","author":"RJ Noelle","year":"2010","unstructured":"Noelle, R. J. & Nowak, E. C. Cellular sources and immune functions of interleukin-9. Nat. Rev. Immunol. 10, 683\u2013687 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"1703_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19672-2","volume":"11","author":"L Liu","year":"2020","unstructured":"Liu, L. et al. Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9. Nat. Commun. 11, 5902 (2020).","journal-title":"Nat. Commun."},{"key":"1703_CR108","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00262-012-1378-2","volume":"62","author":"S Yang","year":"2013","unstructured":"Yang, S. et al. Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunol. Immunother. 62, 727\u2013736 (2013).","journal-title":"Cancer Immunol. Immunother."},{"key":"1703_CR109","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/PL00014051","volume":"46","author":"T Nishimura","year":"2000","unstructured":"Nishimura, T. et al. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother. Pharmacol. 46, 52\u201361 (2000).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"1703_CR110","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/intimm\/dxae015","volume":"36","author":"H Kasuya","year":"2024","unstructured":"Kasuya, H. et al. High CD62L expression predicts the generation of chimeric antigen receptor T cells with potent effector functions. Int. Immunol. 36, 353\u2013364 (2024).","journal-title":"Int. Immunol."},{"key":"1703_CR111","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.4049\/jimmunol.2000007","volume":"205","author":"CG Tucker","year":"2020","unstructured":"Tucker, C. G. et al. Adoptive T cell therapy with IL-12\u2013preconditioned low-avidity T cells prevents exhaustion and results in enhanced T cell activation, enhanced tumor clearance, and decreased risk for autoimmunity. J. Immunol. 205, 1449\u20131460 (2020).","journal-title":"J. Immunol."},{"key":"1703_CR112","doi-asserted-by":"publisher","first-page":"82354","DOI":"10.18632\/oncotarget.10510","volume":"7","author":"XJ Xu","year":"2016","unstructured":"Xu, X. J. et al. Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo. Oncotarget 7, 82354\u201382368 (2016).","journal-title":"Oncotarget"},{"key":"1703_CR113","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3389\/fimmu.2018.00763","volume":"9","author":"K Nakanishi","year":"2018","unstructured":"Nakanishi, K. Unique action of interleukin-18 on T cells and other immune cells. Front. Immunol. 9, 763 (2018).","journal-title":"Front. Immunol."},{"key":"1703_CR114","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiae172","volume":"117","author":"W Li","year":"2024","unstructured":"Li, W. et al. IL-18 primes T cells with an antigen-inexperienced memory phenotype for proliferation and differentiation into effector cells through Notch signaling. J. Leukoc. Biol. 117, iae172 (2024).","journal-title":"J. Leukoc. Biol."},{"key":"1703_CR115","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","volume":"6","author":"S Ghassemi","year":"2018","unstructured":"Ghassemi, S. et al. Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunol. Res. 6, 1100\u20131109 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"1703_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00694-6","volume":"12","author":"J Yang","year":"2022","unstructured":"Yang, J. et al. Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study. Blood Cancer J. 12, 104 (2022).","journal-title":"Blood Cancer J."},{"key":"1703_CR117","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","volume":"6","author":"S Ghassemi","year":"2022","unstructured":"Ghassemi, S. et al. Rapid manufacturing of non-activated potent CAR T cells. Nat. Biomed. Eng. 6, 118\u2013128 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"1703_CR118","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/s44321-024-00055-9","volume":"16","author":"A Jamali","year":"2024","unstructured":"Jamali, A. et al. Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models. EMBO Mol. Med. 16, 784\u2013804 (2024).","journal-title":"EMBO Mol. Med."},{"key":"1703_CR119","unstructured":"Novartis announces T-Charge\u2122, next-generation CAR-T platform with first-in-human data at ASH 2021. Novartis https:\/\/www.novartis.com\/news\/media-releases\/novartis-announces-t-chargetm-next-generation-car-t-platform-first-human-data-ash-2021 (2021)."},{"key":"1703_CR120","doi-asserted-by":"publisher","first-page":"8004","DOI":"10.1200\/JCO.2023.41.16_suppl.8004","volume":"41","author":"AS Sperling","year":"2023","unstructured":"Sperling, A. S. et al. Updated phase I study results of PHE885, a T-charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r\/r multiple myeloma (RRMM). J. Clin. Oncol. 41, 8004\u20138004 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1703_CR121","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","volume":"13","author":"AMJ Dickinson","year":"2023","unstructured":"Dickinson, A. M. J. A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness, shows enhanced CAR T-cell efficacy in preclinical and early clinical development. Cancer Discov. 13, 1982\u20131997 (2023).","journal-title":"Cancer Discov."},{"key":"1703_CR122","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1703_CR123","doi-asserted-by":"publisher","first-page":"876339","DOI":"10.3389\/fimmu.2022.876339","volume":"13","author":"N Watanabe","year":"2022","unstructured":"Watanabe, N., Mo, F. & McKenna, M. K. Impact of manufacturing procedures on CAR T cell functionality. Front. Immunol. 13, 876339 (2022).","journal-title":"Front. Immunol."},{"key":"1703_CR124","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella, M. et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat. Med. 24, 1499\u20131503 (2018).","journal-title":"Nat. Med."},{"key":"1703_CR125","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.3390\/ijms26073206","volume":"26","author":"L Cao","year":"2025","unstructured":"Cao, L., Liu, Y. & Lin, G. Strategies for altering delivery technologies to optimize CAR therapy. Int. J. Mol. Sci. 26, 3206 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"1703_CR126","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","volume":"406","author":"J Xu","year":"2025","unstructured":"Xu, J. et al. In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. Lancet 406, 228\u2013231 (2025).","journal-title":"Lancet"},{"key":"1703_CR127","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809158","volume":"10","author":"A Pfeiffer","year":"2018","unstructured":"Pfeiffer, A. et al. In vivo generation of human CD19- CAR T cells results in B-cell depletion and signs of cytokine release syndrome. EMBO Mol. Med. 10, e9158 (2018).","journal-title":"EMBO Mol. Med."},{"key":"1703_CR128","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/BTT.S291768","volume":"15","author":"ER Hawkins","year":"2021","unstructured":"Hawkins, E. R., D\u2019souza, R. R. & Klampatsa, A. Armored CAR T-cells: the next chapter in T-cell cancer immunotherapy. Biol. Targets Ther. 15, 95\u2013105 (2021).","journal-title":"Biol. Targets Ther."},{"key":"1703_CR129","doi-asserted-by":"publisher","first-page":"5168","DOI":"10.1182\/blood-2006-06-029173","volume":"109","author":"C Hsu","year":"2007","unstructured":"Hsu, C. et al. Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood 109, 5168\u20135177 (2007).","journal-title":"Blood"},{"key":"1703_CR130","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41590-023-01477-2","volume":"24","author":"J Corria-Osorio","year":"2023","unstructured":"Corria-Osorio, J. et al. Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells. Nat. Immunol. 24, 869\u2013883 (2023).","journal-title":"Nat. Immunol."},{"key":"1703_CR131","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi, K. et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat. Biotechnol. 36, 346\u2013351 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1703_CR132","doi-asserted-by":"publisher","unstructured":"Li, L. et al. Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-022-16616-2 (2022).","DOI":"10.1038\/s41598-022-16616-2"},{"key":"1703_CR133","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","volume":"33","author":"KC Conlon","year":"2015","unstructured":"Conlon, K. C. et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 33, 74\u201382 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1703_CR134","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","volume":"26","author":"D Shi","year":"2020","unstructured":"Shi, D. et al. Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials. Clin. Cancer Res. 26, 3979\u20133989 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1703_CR135","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739\u2013748 (2018).","journal-title":"Nat. Med."},{"key":"1703_CR136","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis, T. et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade letter. Nat. Med. 24, 731\u2013738 (2018).","journal-title":"Nat. Med."},{"key":"1703_CR137","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof, K. C. et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 105, 4247\u20134254 (2005).","journal-title":"Blood"},{"key":"1703_CR138","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00639-2","volume":"14","author":"B He","year":"2025","unstructured":"He, B. et al. Interleukin-21 engineering enhances CD19-specific CAR-NK cell activity against B-cell lymphoma via enriched metabolic pathways. Exp. Hematol. Oncol. 14, 51 (2025).","journal-title":"Exp. Hematol. Oncol."},{"key":"1703_CR139","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-024-01792-6","volume":"9","author":"W Zhu","year":"2024","unstructured":"Zhu, W. et al. A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma. Signal Transduct. Target. Ther. 9, 101 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1703_CR140","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1161067","volume":"14","author":"V Carlini","year":"2023","unstructured":"Carlini, V. et al. The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. Front. Immunol. 14, 1161067 (2023).","journal-title":"Front. Immunol."},{"key":"1703_CR141","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","volume":"42","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat. Biotechnol. 42, 1693\u20131704 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1703_CR142","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001544","volume":"10","author":"D Blokon-Kogan","year":"2022","unstructured":"Blokon-Kogan, D. et al. Membrane anchored IL-18 linked to constitutively active TLR4 and CD40 improves human T cell antitumor capacities for adoptive cell therapy. J. Immunother. Cancer 10, e001544 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1703_CR143","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","volume":"20","author":"B Hu","year":"2017","unstructured":"Hu, B. et al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep. 20, 3025\u20133033 (2017).","journal-title":"Cell Rep."},{"key":"1703_CR144","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1182\/blood.2023022293","volume":"144","author":"BD Ng","year":"2024","unstructured":"Ng, B. D. et al. IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model. Blood 144, 171\u2013186 (2024).","journal-title":"Blood"},{"key":"1703_CR145","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","volume":"392","author":"J Svoboda","year":"2025","unstructured":"Svoboda, J. et al. Enhanced CAR T-cell therapy for lymphoma after previous failure. N. Engl. J. Med. 392, 1824\u20131835 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1703_CR146","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","volume":"604","author":"RC Larson","year":"2022","unstructured":"Larson, R. C. et al. CAR T cell killing requires the IFN\u03b3R pathway in solid but not liquid tumours. Nature 604, 563\u2013570 (2022).","journal-title":"Nature"},{"key":"1703_CR147","doi-asserted-by":"publisher","first-page":"e010545","DOI":"10.1136\/jitc-2024-010545","volume":"13","author":"C Kessel","year":"2025","unstructured":"Kessel, C., Rossig, C. & Abken, H. Weal and woe of interleukin-18 in the T cell therapy of cancer. J. Immunother. Cancer 13, e010545 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"1703_CR148","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7004","volume":"42","author":"J Svoboda","year":"2024","unstructured":"Svoboda, J. et al. Safety and efficacy of armored huCART19-IL18 in patients with relapsed\/refractory lymphomas that progressed after anti-CD19 CAR T cells. J. Clin. Oncol. 42, 7004 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1703_CR149","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","volume":"23","author":"MP Avanzi","year":"2018","unstructured":"Avanzi, M. P. et al. Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. Cell Rep. 23, 2130\u20132141 (2018).","journal-title":"Cell Rep."},{"key":"1703_CR150","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","volume":"21","author":"M Chmielewski","year":"2017","unstructured":"Chmielewski, M. & Abken, H. CAR T cells releasing IL-18 convert to T-Bethigh FoxO1low effectors that exhibit augmented activity against advanced solid tumors. Cell Rep. 21, 3205\u20133219 (2017).","journal-title":"Cell Rep."},{"key":"1703_CR151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molimm.2013.03.021","volume":"56","author":"MR Hunter","year":"2013","unstructured":"Hunter, M. R. et al. Chimeric \u03b3c cytokine receptors confer cytokine independent engraftment of human T lymphocytes. Mol. Immunol. 56, 1\u201311 (2013).","journal-title":"Mol. Immunol."},{"key":"1703_CR152","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.ymthe.2021.10.011","volume":"30","author":"A Hombach","year":"2022","unstructured":"Hombach, A. et al. IL12 integrated into the CAR exodomain converts CD8+ T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors. Mol. Ther. 30, 593\u2013605 (2022).","journal-title":"Mol. Ther."},{"key":"1703_CR153","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003633","volume":"10","author":"J Hu","year":"2022","unstructured":"Hu, J. et al. Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. J. Immunother. Cancer 10, e003633 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1703_CR154","doi-asserted-by":"publisher","first-page":"e008572","DOI":"10.1136\/jitc-2023-008572","volume":"12","author":"I S\u00e1nchez-Moreno","year":"2024","unstructured":"S\u00e1nchez-Moreno, I. et al. Tethered IL15-IL15R\u03b1 augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model. J. Immunother. Cancer 12, e008572 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1703_CR155","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40115-1","volume":"14","author":"EHJ Lee","year":"2023","unstructured":"Lee, E. H. J. et al. Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting. Nat. Commun. 14, 4737 (2023).","journal-title":"Nat. Commun."},{"key":"1703_CR156","doi-asserted-by":"publisher","first-page":"6796","DOI":"10.1158\/0008-5472.CAN-14-0079","volume":"74","author":"A Textor","year":"2014","unstructured":"Textor, A. et al. Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFN\u03b3. Cancer Res. 74, 6796\u20136805 (2014).","journal-title":"Cancer Res."},{"key":"1703_CR157","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski, M., Kopecky, C., Hombach, A. A. & Abken, H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71, 5697\u20135706 (2011).","journal-title":"Cancer Res."},{"key":"1703_CR158","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","volume":"21","author":"L Zhang","year":"2015","unstructured":"Zhang, L. et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin. Cancer Res. 21, 2278\u20132288 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1703_CR159","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59971-0","volume":"16","author":"M Beffinger","year":"2025","unstructured":"Beffinger, M. et al. FcRn-silencing of IL-12Fc prevents toxicity of local IL-12 therapy and prolongs survival in experimental glioblastoma. Nat. Commun. 16, 4751 (2025).","journal-title":"Nat. Commun."},{"key":"1703_CR160","doi-asserted-by":"crossref","unstructured":"Murad, J. P. et al. Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery. Nat. Biomed. Eng. 10, 613\u2013629.","DOI":"10.1038\/s41551-025-01509-2"},{"key":"1703_CR161","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41586-025-09212-7","volume":"644","author":"AXY Chen","year":"2025","unstructured":"Chen, A. X. Y. et al. Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery. Nature 644, 241\u2013251 (2025).","journal-title":"Nature"},{"key":"1703_CR162","doi-asserted-by":"publisher","first-page":"eaba1624","DOI":"10.1126\/science.aba1624","volume":"378","author":"GM Allen","year":"2022","unstructured":"Allen, G. M. et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science 378, eaba1624 (2022).","journal-title":"Science"},{"key":"1703_CR163","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41587-019-0398-2","volume":"38","author":"X Ma","year":"2020","unstructured":"Ma, X. et al. Interleukin-23 engineering improves CAR T cell function in solid tumors. Nat. Biotechnol. 38, 448\u2013459 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1703_CR164","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/j.ymthe.2018.07.005","volume":"26","author":"V Golumba-Nagy","year":"2018","unstructured":"Golumba-Nagy, V., Kuehle, J., Hombach, A. A. & Hinrich, A. CD28-\u03b6 CAR T cells resist TGF-\u03b2 repression through IL-2 signaling which can be mimicked by an engineered IL-7 autocrine loop. Mol. Ther. 26, 2218\u20132230 (2018).","journal-title":"Mol. Ther."},{"key":"1703_CR165","doi-asserted-by":"publisher","unstructured":"Zhou, Y. et al. Co-expression of IL-4\/IL-15-based inverted cytokine receptor in CAR-T cells overcomesIL-4 signaling in immunosuppressive pancreatic tumor microenvironment. Biomed. Pharmacother. https:\/\/doi.org\/10.1016\/j.biopha.2023.115740 (2023).","DOI":"10.1016\/j.biopha.2023.115740"},{"key":"1703_CR166","doi-asserted-by":"publisher","unstructured":"Wang, Y. et al. An IL-4\/21 inverted cytokine receptor improving CAR-T cell potency inimmunosuppressive solid-tumor microenvironment Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.01691 (2019).","DOI":"10.3389\/fimmu.2019.01691"},{"key":"1703_CR167","doi-asserted-by":"publisher","first-page":"1662238","DOI":"10.3389\/fimmu.2025.1662238","volume":"16","author":"R Rane","year":"2025","unstructured":"Rane, R. et al. Chimeric switch and inverted cytokine receptors in T cell therapy: reprogramming T cells to overcome immune suppression in the solid tumor microenvironment. Front. Immunol. 16, 1662238 (2025).","journal-title":"Front. Immunol."},{"key":"1703_CR168","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1126\/science.aar3246","volume":"359","author":"JT Sockolosky","year":"2018","unstructured":"Sockolosky, J. T. et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science 359, 1037\u20131042 (2018).","journal-title":"Science"},{"key":"1703_CR169","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-143483","volume":"136","author":"P-J Aspuria","year":"2020","unstructured":"Aspuria, P.-J. et al. OrthoCARs: engineered human IL-2\/IL-2Rb orthogonal pairs selectively enhance CAR T cell antitumorefficacy. Blood 136, 35\u201335 (2020).","journal-title":"Blood"},{"key":"1703_CR170","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/s41586-025-09393-1","volume":"645","author":"Y Zhao","year":"2025","unstructured":"Zhao, Y. et al. Expanding the cytokine receptor alphabet reprograms T cells into diverse states. Nature 645, 1039\u20131050 (2025).","journal-title":"Nature"},{"key":"1703_CR171","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2025.10.021","volume":"59","author":"S Castelli","year":"2026","unstructured":"Castelli, S. et al. IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing anti-tumor efficacy. Immunity 59, 195\u2013212.e11 (2026).","journal-title":"Immunity"},{"key":"1703_CR172","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-022-04801-2","volume":"607","author":"A Kalbasi","year":"2022","unstructured":"Kalbasi, A. et al. Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature 607, 360\u2013365 (2022).","journal-title":"Nature"},{"key":"1703_CR173","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.878209","volume":"13","author":"G L\u00f3pez-Cantillo","year":"2022","unstructured":"L\u00f3pez-Cantillo, G., Urue\u00f1a, C., Camacho, B. A. & Ram\u00edrez-Segura, C. CAR-T cell performance: how to improve their persistence? Front. Immunol. 13, 878209 (2022).","journal-title":"Front. Immunol."},{"key":"1703_CR174","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577027","volume":"11","author":"J Gust","year":"2020","unstructured":"Gust, J., Ponce, R., Liles, W. C., Garden, G. A. & Turtle, C. J. Cytokines in CAR T cell-associated neurotoxicity. Front. Immunol. 11, 577027 (2020).","journal-title":"Front. Immunol."},{"key":"1703_CR175","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-014-0026-0","volume":"2","author":"JP Dutcher","year":"2014","unstructured":"Dutcher, J. P. et al. High dose interleukin-2 (Aldesleukin)\u2014expert consensus on best management practices\u20142014. J. Immunother. Cancer 2, 26 (2014).","journal-title":"J. Immunother. Cancer"},{"key":"1703_CR176","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.952231","volume":"13","author":"Z Jia","year":"2022","unstructured":"Jia, Z. et al. IL12 immune therapy clinical trial review: novel strategies for avoiding CRS-associated cytokines. Front. Immunol. 13, 952231 (2022).","journal-title":"Front. Immunol."},{"key":"1703_CR177","doi-asserted-by":"publisher","first-page":"4945","DOI":"10.1158\/1078-0432.CCR-18-3468","volume":"25","author":"KC Conlon","year":"2019","unstructured":"Conlon, K. C. et al. IL15 by continuous intravenous infusion to adult patients with solid tumors in a phase I trial induced dramatic NK-cell subset expansion. Clin. Cancer Res. 25, 4945\u20134954 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1703_CR178","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","volume":"3","author":"L Y\u00e1\u00f1ez","year":"2019","unstructured":"Y\u00e1\u00f1ez, L., S\u00e1nchez-Escamilla, M. & Perales, M. A. CAR T cell toxicity: current management and future directions. HemaSphere 3, e186 (2019).","journal-title":"HemaSphere"},{"key":"1703_CR179","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","volume":"31","author":"L Tang","year":"2023","unstructured":"Tang, L., Pan, S., Wei, X., Xu, X. & Wei, Q. Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development. Mol. Ther. 31, 3146\u20133162 (2023).","journal-title":"Mol. Ther."},{"key":"1703_CR180","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","volume":"28","author":"M Zhang","year":"2022","unstructured":"Zhang, M. et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia\/lymphoma. Clin. Cancer Res. 28, 2830\u20132843 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1703_CR181","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj6251","volume":"10","author":"L Lu","year":"2024","unstructured":"Lu, L. et al. Enhancing the safety of CAR-T cell therapy: synthetic genetic switch for spatiotemporal control. Sci. Adv. 10, eadj6251 (2024).","journal-title":"Sci. Adv."},{"key":"1703_CR182","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1053\/j.seminhematol.2024.07.003","volume":"61","author":"D Blud","year":"2024","unstructured":"Blud, D., Rubio-Reyes, P., Perret, R. & Weinkove, R. Tuning CAR T-cell therapies for efficacy and reduced toxicity. Semin. Hematol. 61, 333\u2013344 (2024).","journal-title":"Semin. Hematol."}],"updated-by":[{"DOI":"10.1038\/s41551-026-01783-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000}}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01703-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01703-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01703-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:02:19Z","timestamp":1789509739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01703-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":182,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["1703"],"URL":"https:\/\/doi.org\/10.1038\/s41551-026-01703-w","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41551-026-01783-8","URL":"https:\/\/doi.org\/10.1038\/s41551-026-01783-8","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.K. has received honoraria from Cymab, Plectonic, TCR2 Inc., Galapagos, Novartis, Regeneron, BMS, Miltenyi and GSK. S.K. is an inventor of several patents in the field of immuno-oncology. S.K. has received licence fees from TCR2 Inc. and Carina Biotech. S.K. has received research support from Tabby Therapeutics, TCR2 Inc., Plectonic, Catalym and Arcus Bioscience for work unrelated to the manuscript. D.S., C.K. and D.V., are current or former employees of Roche and hold ownership of Roche stocks and patents\/royalties. H.L. has received travel grants and consultant fees from BMS and Merck, Sharp and Dohme (MSD). H.L. is a co-founder of Glycocalyx Therapeutics. S.T. has received honoraria from Amgen, BMS, GSK, Janssen, Pfizer, Sanofi, Takeda, Kyowa Kirin and Oncopeptides. A.Z. has received consulting\/advisor fees from Bristol-Myers Squibb, Merck Sharp & Dohme, Hoffmann\u2013La Roche, NBE Therapeutics and Engimmune, and maintains further non-commercial research agreements with Hoffmann\u2013La Roche, T3 Pharma, Bright Peak Therapeutics and AstraZeneca. T.D.d.G. is an inventor on several patents in the field of immuno-oncology as an employee of Amsterdam UMC, and is scientific advisor to Mendus and Vivaldi Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}